Roche will present a number of studies across its comprehensive oncology portfolio, covering a broad range of cancers including bladder, lung and breast will be presented at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain.
Roche noted that a total of 100 abstracts and 15 late-breaking abstracts that include a Roche medicine will be presented at this year’s congress.
Among the key datasets across a broad range of diseases at ESMO this year, Roche will also present the results from its Tecentriq combination study in people with previously untreated advanced bladder cancer, the first positive Phase III cancer immunotherapy trial in this setting.
Sandra Horning, Roche’s Chief Medical Officer and Head of Global Product Development also said that the company will present data from its Phase III Tecentriq monotherapy study in previously untreated advanced lung cancer.
“We will also share data from a study using Foundation Medicine’s liquid (blood) biopsy, a more patient-friendly approach to diagnosing and treating cancer. The results of the first cohort of this study involving ALK+ non-small cell lung cancer patients who received Alecensa will be presented at the congress,” she said.
The ESMO Congress is the appointment in Europe for clinicians, researchers, patient advocates, journalists and the pharmaceutical industry from all over the world to get together, learn about the latest advances in oncology and translate science into better cancer patient care, to be held in Barcelona, Spain from September 27 until October 1, 2019.